Research programme: RDX 02 - Infex Therapeutics/Redx Pharma
Alternative Names: RDX 02 - Infex Therapeutics/Redx PharmaLatest Information Update: 03 Mar 2023
At a glance
- Originator Redx Pharma
- Developer Infex Therapeutics; Redx Pharma
- Class Antibacterials
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Gram-negative infections